Novo Nordisk A/S Common Stock (NVO)

Lilly's weight loss drugs have been delivering blockbuster revenue.

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

And he may be right.

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Eli Lilly has more to offer than some investors realize.

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

The weight loss drug market may reach almost $100 billion in a few years.

High hopes for a freshly approved drug might not be realized, if early data is any indication.

A rival company's trial results had a negative impact on Agios' stock this week.

Novo Nordisk stock has been stuck in a downward spiral for quite some time.

Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

Telehealth investors weigh Amazon’s new anti-obesity drug push against this platform’s recent rapid growth, today, April 21, 2026.

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

The stock could have plenty of room to run from current levels.

There are other factors to consider before investing in this -- or any other -- healthcare company.

Lilly's revenue has soared thanks to its obesity drugs.

And can Novo Nordisk catch up to its rival in the weight loss market?

AbbVie is making progress in this market, but it is still far behind the leader.